Activity Details

1.0 Contact Hour
Released: August 27, 2018
Expires: August 26, 2019
1 hour to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for oncology nurses, advanced practitioners, pharmacists, pharmacy technicians, and other allied healthcare professionals involved in the team-based management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the risks, benefits, and differentiation points among CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer with the healthcare team and patients.
  • Evaluate proper dosing and administration of oral CDK 4/6 inhibitors used in the treatment of HR-positive/HER2-negative advanced breast cancer.
  • Enhance patient education through shared decision-making strategies regarding therapy selection and the importance of oral therapy compliance to maximize therapeutic outcomes.
  • Educate patients on potential adverse events associated with CDK 4/6 inhibitors.
  • Develop strategies to anticipate, monitor and manage adverse events with oral CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer to maximize the benefits of these therapies.

Activity Description

The American Cancer Society estimated that in 2017 there were 255,180 new cases of breast cancer and 41,070 deaths due to breast cancer in the United States. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.

Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Differentiating among the agents that comprise this novel class will be essential practice skills that oncology advanced practitioners such as nurses and pharmacists will need to become more familiar with to advance patient care and support.

New oral agents are revolutionizing breast cancer care, and data show that patient adherence to the full duration of therapy is critical to realize the positive effects of these agents on tumor control and patient survival. Nurses and pharmacists can play a critical role in improving patient adherence to oral therapy, from treatment decision support and monitoring to management and patient counseling.

This activity will review these oral therapies, including risk and benefits, barriers to adherence, side effect monitoring and management and patient counseling on aspects such as dosing and safe handling of oral therapies. This will be coupled with education about shared decision-making strategies to achieve increased patient satisfaction, better adherence to treatment plans, greater treatment engagement, and better quality decision making.

Statement of Educational Need

The goal of this activity is to provide education about oral CDK 4 and 6 inhibitors for the treatment of HR+/HER2− advanced or metastatic breast cancer so nurses, pharmacists, and other healthcare professionals are able to educate, counsel, and support patients regarding benefits, dosing, adherence, and side effects of therapies to make informed decisions with the goal of improving patient outcomes.


Pharmacy Co-Chairperson
Michael L. Brandt, PharmD, FASHP
Oncology Infusion Pharmacist
Cancer and Blood Specialties Center
Rockwood Clinic, MultiCare Health System
Spokane, Washington

Nurse Co-Chairperson
Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
Stacy Goldstein Breast Center
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Reported Financial Relationship

Michael L. Brandt, PharmD, FASHP

Michael L. Brandt, PharmD, FASHP, has no real or apparent conflicts of interest to report

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: PUMA Biotechnology

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Pharmacists/Pharmacy Technicians
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (JA4008106-0000-18-039-H01-P and JA4008106-0000-18-039-H01-T).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.